Top 5 Stocks To Buy For 2014

Here are some of these which every subscriber should know-

PF Entitles for Pension Too

There are two elements in EPF- Provident Fund and EPS or Employee Pension Scheme introduced in 1995. The entire contribution of subscriber (12% of basic +DA) goes towards provident fund but from the employer contribution of 12%, 8.33% goes towards EPS (subject to max. Rs 541) and rest added to your provident fund account. The pension on retirement is linked to the number of years in service and the average salary drawn in the year before retirement. This contribution in EPS helps in building a corpus for your pension. Although the maximum pension has been limited to Rs 3500 p.m., it is possible to get a higher pension if employer contributes on basis of employee actual pay and not mandated amount of Rs 6500 p.m. There is also provision in the law where you can receive your EPS money as a lump sum along with your PF. The benefit will be linked to your last year�� average salary and number of years in service.  For receiving pension benefits one should be 58 years of age and should have completed 10 years of service without any withdrawal. But there are provisions where if you retire before 58 you will still receive the pension but a reduced amount. Lastly, your family is entitled to the pension if you do not survive the required period, provided they meet some specified conditions.

Top 5 Stocks To Buy For 2014: Chelsea Therapeutics International Ltd.(CHTP)

Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutic products for the treatment of various human diseases. It is involved in developing Droxidopa, a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with primary autonomic failure and falls related to NOH in Parkinson?s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, adult attention deficit hyperactivity disorder, chronic fatigue syndrome, and freezing of gait in PD and down syndrome. The company intends to market its Droxidopa drug under the Northera brand name. It also engages in developing a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn?s disease, ankylosing spondylitis, uveitis, psoriatic arthritis, inflammatory bowel disease, cancer, and other immunological disorders. The company?s molecule products include a portfolio of metabolically inert antifolate molecules consisting of CH-1504 and CH-4051, which are orally available molecules with anti-inflammatory, autoimmune, and anti-tumor properties that inhibit various key enzymes required for cell proliferation; and a portfolio of dihydroorotate dehydrogenase, known as the I-3D portfolio, for applications in autoimmune diseases and transplantation. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.

Advisors' Opinion:

• [By Roberto Pedone]

  Chelsea Therapeutics (CHTP)
  is a specialty pharmaceutical company focused on acquisition, development and commercialization of pharmaceutical products for the treatment of a variety of human diseases. This stock closed up 9% to $2.89 in Thursday's trading session.

  Thursday's Range: $2.55-$2.98
  
  52-Week Range: $0.73-$3.25
  
  Thursday's Volume: 1.74 million
  
  Three-Month Average Volume: 1.14 million

  From a technical perspective, CHTP ripped sharply higher here right off its 50-day moving average of $2.55 with above-average volume. This stock has been uptrending strong for the last two months, with shares moving higher from its low of $1.78 t its recent high of $3.25. During that move, shares of CHTP have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CHTP within range of triggering a major breakout trade. That trade will hit if CHTP manages to take out some near-term overhead resistance levels at $3 to its 52-week high at $3.25 with high volume.

  Traders should now look for long-biased trades in CHTP as long as it's trending above its 50-day at $2.55 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.14 million shares. If that breakout triggers soon, then CHTP will set up to enter new 52-week-high territory above $3.25, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $4.21 to $4.40.

Top 5 Stocks To Buy For 2014: Guyana Goldfields New Com Npv(GUY.TO)

Guyana Goldfields Inc. engages in the acquisition, exploration, evaluation, and development of gold resource properties in the Guiana Shield of South America. The company owns a 100% interest in the Aurora gold project located in Guyana. It also holds interests in the Aranka properties, including Sulphur Rose, North Ridge, Wynamu, Kopang, and Parika Hills properties covering an area of approximately 307,589 acres located in the Aranka district of Guyana. Guyana Goldfields Inc. is headquartered in Toronto, Canada.

Top Small Cap Stocks To Invest In 2014: Superior Resources Ltd(SPQ.AX)

Superior Resources Limited engages in the exploration of base metals in northwest Queensland, Australia. It primarily explores for copper, lead, zinc, and silver deposits, as well as for uranium, phosphate, and diamonds. The company holds approximately 18 exploration permits and applications that are grouped into 5 projects, which cover approximately 4,000 square kilometers in the northwest Queensland minerals province. It primarily focuses on the exploration of the Dajarra, Victor, and Nicholson projects that are situated in the Mount Isa area of northwest Queensland. Superior Resources Limited is based in Brisbane, Australia.

Top 5 Stocks To Buy For 2014: Wipro Limited(WIT)

Wipro Limited provides information technology (IT) products and services, consumer care and lighting products, and infrastructure engineering services primarily in India, the United States, and Europe. The company?s IT Services segment offers IT and IT enabled services, including software application development, application maintenance, research, and development services for hardware and software design, data center outsourcing services, and business process outsourcing services. Its IT Products segment produces and sells a range of Wipro personal desktop computers, Wipro servers, and Wipro notebooks. This segment also operates as a reseller of desktops, servers, notebooks, storage products, networking solutions, and packaged software for various international brands. The company?s Consumer Care and Lighting segment manufactures, distributes, and sells personal care products, baby care products, lighting products, and hydrogenated cooking oils in India and rest of Asia. Wipro Limited also manufactures and sells hydraulic cylinders, truck cylinders, and their components and solutions to original equipment manufacturers, as well as provides water treatment systems and solutions. The company was founded in 1945 and is headquartered in Bangalore, India.

Top 5 Stocks To Buy For 2014: Oxford Biomedica(OXB.L)

Oxford BioMedica plc, a biopharmaceutical company, engages in designing and developing gene-based medicines and therapeutic vaccines for the treatment of cancer, age-related or inherited neurodegenerative disorders, and ocular diseases in the United States and the United Kingdom. Its technology platform includes LentiVector, a gene delivery system that targets diseases of the central nervous system and the eye; 5T4, a tumour antigen targeted for anti-cancer therapy; Hi-8 PrimeBoost technology to stimulate potent and specific cellular immune responses against diseased cells; Gene-Directed Enzyme Prodrug Therapy, a therapeutic strategy for safety and effectiveness of prodrugs; and Anti-Angiogenisis technology, an anti-cancer therapeutic strategy to deliver the genes for endostatin and angiostatin using viral vectors. The company?s product pipeline comprises ProSavin, a therapeutic for the treatment of Parkinson?s disease that is in a Phase I/II dose escalating clinical tri al; RetinoStat, a treatment for neovascular ?wet? age-related macular degeneration and diabetic retinopathy; StarGen for the treatment of Stargardt disease; UshStat for the treatment of Usher syndrome 1B; EncorStat for the prevention of corneal graft rejection; TroVax, a therapeutic cancer vaccine; Hi-8 MEL, a therapeutic vaccine for metastatic melanoma; and MetXia, a gene-directed enzyme prodrug therapy for pancreatic cancer. Its products also consist of Anti-5T4, a pre-clinical stage antibody for treating cancer, as well as products under research comprising MoNuDin for the treatment of motor neuron disease, and EndoAngio-GT, an anti-angiogenic therapy for cancer. The company has partnerships and licensing agreements with Sanofi-Aventis, Sigma-Aldrich, Pfizer, Biogen Idec, Emergent BioSolutions, GlaxoSmithKline, Merck & Co, MolMed, VIRxSYS Corporation, Bavarian Nordic, and Emergent BioSolutions for its products and technologies. Oxford BioMedica plc is based in Oxford, t he United Kingdom.